89 个 · 按相关度排序
Use when receiving code review feedback, before implementing suggestions, especially if feedback seems unclear or technically questionable - requires technical rigor and verification, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。
Conversation patterns and interaction protocols for multi-agent systems. Covers request/response, pub/sub, blackboard, delegation chains, debate, critique, consensus, fan-out/fan-in, supervisor-worker, and peer negotiation. Deep analysis of AutoGen conversation patterns, CrewAI delegation, LangGraph state passing, and FIPA-ACL performatives. Teaches how to design what agents say to each other and in what order. Activate on: "agent conversation", "agent protocol", "multi-agent debate", "agent delegation", "supervisor worker pattern", "agent voting", "consensus protocol", "fan-out fan-in", "agent negotiation", "blackboard pattern", "agent dialogue", "conversation topology", "agent handoff". NOT for: wire format or serialization (use agent-interchange-formats), orchestration infrastructure (use agentic-infrastructure-2026), single agent behavior (use agentic-patterns).
中文简介正在准备中。当前显示原文说明。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
中文简介正在准备中。当前显示原文说明。
Use when receiving code review feedback, before implementing suggestions, especially if feedback seems unclear or technically questionable - requires technical rigor and verification, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。
Use when receiving code review feedback, before implementing suggestions, especially if feedback seems unclear or technically questionable - requires technical rigor and verification, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。
Use when receiving code review feedback, before implementing suggestions, especially if feedback seems unclear or technically questionable - requires technical rigor and verification, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。
Use when receiving code review feedback, before implementing suggestions, especially if feedback seems unclear or technically questionable - requires technical rigor and verification, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。
Artificial intelligence-driven transformative applications in disease ... — In cancer diagnostics, AI systems have achieved breakthrough performances
中文简介正在准备中。当前显示原文说明。
Use when the user asks to "triage our comments, DMs, and mentions", "draft replies to this thread", "can we repost this fan post", or "set up inbox SLAs and an escalation path"; produces a ranked triage queue with register detection (sincere / ironic / performative / parasocial, sentiment-inversion table included — "this is so bad" under a comedy register is praise), a commenter taxonomy (troll monitor-only / rager / misguided / unhappy-customer / advocate) with a response-tier ladder and per-channel SLAs, an escalation matrix ending at the crisis path, a moderation ladder plus house rules for owned spaces, and a UGC curation-and-rights mode whose dated permission entries route to the channel registry — every reply is a ranked DRAFT a human posts; nothing is ever auto-sent. Not for launch-window feedback triage — use launch-feedback-synthesizer. 评论私信提及分诊/语域识别/回复草稿/UGC授权
中文简介正在准备中。当前显示原文说明。
Receive and act on code review feedback with technical rigor, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。
Use when receiving code review feedback, before implementing suggestions, especially if feedback seems unclear or technically questionable - requires technical rigor and verification, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。
Use when receiving code review feedback, before implementing suggestions, especially if feedback seems unclear or technically questionable - requires technical rigor and verification, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。
Finds the most informative session recording linked to an error tracking issue. Use when a user has an error tracking issue ID and wants to watch a replay showing what the user was doing when the error occurred. Ranks linked sessions by recency, activity score, and journey completeness, then summarizes the pre-error context. Replaces blind session picking from potentially hundreds of linked recordings.
中文简介正在准备中。当前显示原文说明。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
中文简介正在准备中。当前显示原文说明。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
中文简介正在准备中。当前显示原文说明。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
中文简介正在准备中。当前显示原文说明。
Use when receiving code review feedback, before implementing suggestions, especially if feedback seems unclear or technically questionable - requires technical rigor and verification, not performative agreement or blind implementation
中文简介正在准备中。当前显示原文说明。